Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality

Massimo Imazio, Antonio Brucato, George Lazaros, Alessandro Andreis, Mirko Scarsi, Allan Klein, Gaetano Maria De Ferrari, Yehuda Adler

Research output: Contribution to journalReview articlepeer-review

51 Scopus citations

Abstract

: The COVID-19 pandemic is challenging our cardiovascular care of patients with heart diseases. In the setting of pericardial diseases, there are two possible different scenarios to consider: the patient being treated for pericarditis who subsequently becomes infected with SARS-CoV-2, and the patient with COVID-19 who develops pericarditis or pericardial effusion. In both conditions, clinicians may be doubtful regarding the safety of nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, colchicine, and biological agents, such as anti-IL1 agents (e.g. anakinra), that are the mainstay of therapy for pericarditis.For NSAIDs, there is no clear scientific evidence linking ibuprofen and other NSAIDs to worsening of COVID-19; however, it seems prudent to continue them, if necessary to control pericarditis, and on the other hand, to prefer paracetamol for fever and systemic symptoms related to COVID-19. Treatments with corticosteroids, colchicine, and anakinra appear well tolerated in the context of COVID-19 infection and are currently actively evaluated as potential therapeutic options for COVID infection at different stages of the disease. On this basis, currently most treatments for pericarditis do not appear contraindicated also in the presence of possible COVID-19 infection and should not be discontinued, and some (corticosteroids, colchicine, and anakinra) can be considered to treat both conditions.

Original languageEnglish
Pages (from-to)625-629
Number of pages5
JournalJournal of Cardiovascular Medicine
Volume21
Issue number9
DOIs
StatePublished - 1 Sep 2020

Fingerprint

Dive into the research topics of 'Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality'. Together they form a unique fingerprint.

Cite this